AstraZeneca’s hopes of positioning its PD ... was no better than placebo at extending disease-free survival (DFS). The trial enrolled patients with NSCLC that had PD-L1 expression on 25% or ...
Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...
Steve Simusokwe, a young activist from Karonga, recently expressed his remorse regarding his past involvement in protests ...